You are here

Article Text

Article menu
Download PDFPDF
Editor’s column
In the thrombectomy era, triage in the field improves care
  1. Johanna T Fifi1,
  2. Guilherme Dabus2,
  3. William J Mack3,
  4. J Mocco1,
  5. Lee Pride4,
  6. Adam S Arthur5,
  7. Felipe C Albuquerque6
  1. 1 The Mount Sinai Health System, New York, USA
  2. 2 Department of Interventional Neuroradiology and Neuroendovascularl Surgery, Miami Cardiac and Vascular Institute and Baptist Neuroscience Center, Miami, Florida, USA
  3. 3 Department of Neurosurgery, University of Southern California, Los Angeles, California, USA
  4. 4 Department of Neuroradiology, UT Southwestern, Dallas, Texas, USA
  5. 5 UT Department of Neurosurgery/Semmes-Murphey Clinic, Memphis, Tennessee, USA
  6. 6 Department of Neurological Surgery, Barrow Neurological Institute, Phoenix, Arizona, USA
  1. Correspondence to Dr Johanna T Fifi, Department of Neurosurgery, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Johanna.Fifi{at}mountsinai.org

http://dx.doi.org/10.1136/neurintsurg-2018-014136

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the comments by Leira and Savitz1 in the June 2018 issue of Stroke regarding ischemic stroke triage, administration of intravenous tissue plasminogen activator (IV tPA), and mechanical thrombectomy. Although the topic is timely and the authors’ insights clearly expressed, we disagree with both the concluding statements and the supporting arguments that lead to these inferences. Current evidence does not suggest that advances in mechanical thrombectomy are occurring at the expense of IV tPA only treated patients, and primary stroke centers (PSCs) are not at an existential risk. We offer the following thoughts:

    Endovascular therapy (ET) is now the standard of care for emergent large vessel occlusion (ELVO) acute ischemic stroke following the overwhelmingly positive outcomes from multiple randomized trials that compared ET with IV tPA or best medical management.2–8 It is one of the most effective therapies available in modern medicine.2–8 It was estimated that only 10–15% of patients with acute ischemic stroke were eligible for ET.9–11 In the past year, the number of eligible patients has increased further due to the demonstrated efficacy of treatment for …

    View Full Text

    Footnotes

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent Not required.

    • Provenance and peer review Commissioned; internally peer reviewed.